Company Overview
NEWAMSTERDAM PHARMA CO N.V.
NAMSRevenue vs. Cost of Revenue
Revenue
Cost of Revenue
Total Operating Expenses vs. Operating Income
Total Operating Expenses
Operating Income
Net Income
Net Income
Revenue
23M
2025 FY
Net Income
-204M
2025 FY
Shares Outstanding
118M
2025 FY
EPS
-1.72USD
2025 FY
Company Information
SIC Code
2834
CIK Code
1936258
Exchange
Nasdaq
Location
NL